Published in Cancers (Basel) on March 29, 2011
Peptidylarginine deiminase 2-catalyzed histone H3 arginine 26 citrullination facilitates estrogen receptor α target gene activation. Proc Natl Acad Sci U S A (2012) 1.35
Estrogen receptors regulate an inflammatory pathway of dendritic cell differentiation: mechanisms and implications for immunity. Horm Behav (2012) 1.12
Estrogen receptors regulate innate immune cells and signaling pathways. Cell Immunol (2015) 1.12
PELP1 oncogenic functions involve CARM1 regulation. Carcinogenesis (2013) 0.99
The many faces of estrogen signaling. Biochem Med (Zagreb) (2014) 0.84
Estradiol inhibits Th17 cell differentiation through inhibition of RORγT transcription by recruiting the ERα/REA complex to estrogen response elements of the RORγT promoter. J Immunol (2015) 0.81
Histone methylation modifiers in cellular signaling pathways. Cell Mol Life Sci (2015) 0.81
Novel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cells. Breast Cancer Res Treat (2015) 0.80
Therapeutic perspectives of epigenetically active nutrients. Br J Pharmacol (2014) 0.80
Potential of epigenetic therapies in non-cancerous conditions. Front Genet (2014) 0.79
Alternatively spliced tissue factor synergizes with the estrogen receptor pathway in promoting breast cancer progression. J Thromb Haemost (2015) 0.78
Estrogens Correlate with PELP1 Expression in ER Positive Breast Cancer. PLoS One (2015) 0.76
Genistein potentiates the effect of 17-beta estradiol on human hepatocellular carcinoma cell line. Adv Biomed Res (2016) 0.76
A New Role for ERα: Silencing via DNA Methylation of Basal, Stem Cell, and EMT Genes. Mol Cancer Res (2016) 0.75
Toward breaking the histone code: bayesian graphical models for histone modifications. Circ Cardiovasc Genet (2013) 0.75
Estrogen Receptor-Dependent Regulation of Dendritic Cell Development and Function. Front Immunol (2017) 0.75
Expression of Estrogen Receptor Alpha in Malignant Melanoma. Adv Biomed Res (2017) 0.75
Bivalent Epigenetic Control of Oncofetal Gene Expression in Cancer. Mol Cell Biol (2017) 0.75
Epigenetic Mechanisms of Tamoxifen Resistance in Luminal Breast Cancer. Diseases (2017) 0.75
The epigenomics of cancer. Cell (2007) 30.91
Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell (2004) 21.30
Active genes are tri-methylated at K4 of histone H3. Nature (2002) 15.68
Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem (1994) 10.75
Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell (2003) 10.42
Histone acetyltransferases. Annu Rev Biochem (2001) 10.00
Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev (1999) 7.42
Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev (2007) 6.71
Transitions in distinct histone H3 methylation patterns at the heterochromatin domain boundaries. Science (2001) 6.60
Physical association and coordinate function of the H3 K4 methyltransferase MLL1 and the H4 K16 acetyltransferase MOF. Cell (2005) 6.12
Correlation between histone lysine methylation and developmental changes at the chicken beta-globin locus. Science (2001) 6.00
Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell (2007) 5.49
Human PAD4 regulates histone arginine methylation levels via demethylimination. Science (2004) 5.46
Estrogen receptors: how do they signal and what are their targets. Physiol Rev (2007) 5.27
Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase. Cell (1999) 5.23
Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology (2003) 4.96
Histone methylation-dependent mechanisms impose ligand dependency for gene activation by nuclear receptors. Cell (2007) 4.45
Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev (2004) 3.74
JMJD6 is a histone arginine demethylase. Science (2007) 3.48
High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell (2004) 3.46
Connections and regulation of the human estrogen receptor. Science (2002) 3.26
Epigenetic modifications as therapeutic targets. Nat Biotechnol (2010) 3.16
Regulation of tumor angiogenesis by EZH2. Cancer Cell (2010) 3.10
DNA oxidation as triggered by H3K9me2 demethylation drives estrogen-induced gene expression. Science (2008) 3.09
Nuclear receptor coactivators. Curr Opin Cell Biol (1997) 2.96
Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. Nat Cell Biol (2001) 2.93
Chromatin remodeling and cancer, Part I: Covalent histone modifications. Trends Mol Med (2007) 2.60
Sin3: a flexible regulator of global gene expression and genome stability. Curr Genet (2004) 2.60
Nongenomic actions of steroid hormones. Nat Rev Mol Cell Biol (2003) 2.54
Downregulation of histone H3 lysine 9 methyltransferase G9a induces centrosome disruption and chromosome instability in cancer cells. PLoS One (2008) 2.52
Jmjd6 catalyses lysyl-hydroxylation of U2AF65, a protein associated with RNA splicing. Science (2009) 2.37
PRMT 3, a type I protein arginine N-methyltransferase that differs from PRMT1 in its oligomerization, subcellular localization, substrate specificity, and regulation. J Biol Chem (1998) 2.35
Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state. Nat Rev Cancer (2007) 2.30
Protein arginine-methyltransferase-dependent oncogenesis. Nat Cell Biol (2007) 2.14
Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res (2006) 2.10
Nuclear and extranuclear pathway inputs in the regulation of global gene expression by estrogen receptors. Mol Endocrinol (2008) 2.09
AIB1/SRC-3 deficiency affects insulin-like growth factor I signaling pathway and suppresses v-Ha-ras-induced breast cancer initiation and progression in mice. Cancer Res (2004) 2.07
The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol (2002) 2.03
Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemother Pharmacol (2005) 2.01
Small molecule regulators of protein arginine methyltransferases. J Biol Chem (2004) 1.99
Histone arginine methylation. FEBS Lett (2010) 1.95
Identification of the MLL2 complex as a coactivator for estrogen receptor alpha. J Biol Chem (2006) 1.92
Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting. Mol Interv (2005) 1.92
Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Sci (2006) 1.90
Nuclear receptors: coactivators, corepressors and chromatin remodeling in the control of transcription. J Mol Endocrinol (1999) 1.85
A tale of histone modifications. Genome Biol (2001) 1.85
Menin links estrogen receptor activation to histone H3K4 trimethylation. Cancer Res (2006) 1.83
CARM1 regulates estrogen-stimulated breast cancer growth through up-regulation of E2F1. Cancer Res (2008) 1.83
TDRD3 is an effector molecule for arginine-methylated histone marks. Mol Cell (2010) 1.80
Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene (2005) 1.79
Estrogen receptor isoform-specific regulation of endogenous gene expression in human osteoblastic cell lines expressing either ERalpha or ERbeta. J Cell Biochem (2003) 1.76
Acetylation of estrogen receptor alpha by p300 at lysines 266 and 268 enhances the deoxyribonucleic acid binding and transactivation activities of the receptor. Mol Endocrinol (2006) 1.73
The polycomb group protein enhancer of zeste homolog 2 (EZH 2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype. Oncogene (2005) 1.73
Coactivator-associated arginine methyltransferase 1 (CARM1) is a positive regulator of the Cyclin E1 gene. Proc Natl Acad Sci U S A (2006) 1.69
Retracted Metastasis-associated protein 1 deregulation causes inappropriate mammary gland development and tumorigenesis. Development (2004) 1.67
Mice lacking the amplified in breast cancer 1/steroid receptor coactivator-3 are resistant to chemical carcinogen-induced mammary tumorigenesis. Cancer Res (2005) 1.60
The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr Med Chem Anticancer Agents (2003) 1.58
Functional and biological properties of the nuclear receptor coregulator PELP1/MNAR. Nucl Recept Signal (2007) 1.48
Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells. Mol Cancer Res (2010) 1.46
Xenoestrogen-induced regulation of EZH2 and histone methylation via estrogen receptor signaling to PI3K/AKT. Mol Endocrinol (2010) 1.42
The histone demethylase JMJD2B is regulated by estrogen receptor alpha and hypoxia, and is a key mediator of estrogen induced growth. Cancer Res (2010) 1.40
PELP1 is a reader of histone H3 methylation that facilitates oestrogen receptor-alpha target gene activation by regulating lysine demethylase 1 specificity. EMBO Rep (2010) 1.39
Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations. Clin Cancer Res (2006) 1.38
Genomic collaboration of estrogen receptor alpha and extracellular signal-regulated kinase 2 in regulating gene and proliferation programs. Mol Cell Biol (2010) 1.38
Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Cancer Biol Ther (2010) 1.37
Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue. Breast Cancer Res Treat (2001) 1.34
Expression levels of estrogen receptor-alpha, estrogen receptor-beta, coactivators, and corepressors in breast cancer. Clin Cancer Res (2000) 1.30
Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. J Cell Physiol (2007) 1.30
Oncogenic potential of the nuclear receptor coregulator proline-, glutamic acid-, leucine-rich protein 1/modulator of the nongenomic actions of the estrogen receptor. Cancer Res (2007) 1.28
The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminal-like subtype. Breast Cancer Res Treat (2009) 1.27
Essential phosphatases and a phospho-degron are critical for regulation of SRC-3/AIB1 coactivator function and turnover. Mol Cell (2008) 1.27
Deregulation of histone lysine methyltransferases contributes to oncogenic transformation of human bronchoepithelial cells. Cancer Cell Int (2008) 1.26
Estrogen-induced rat breast carcinogenesis is characterized by alterations in DNA methylation, histone modifications and aberrant microRNA expression. Cell Cycle (2007) 1.21
Protein arginine deiminase 4: a target for an epigenetic cancer therapy. Cell Mol Life Sci (2010) 1.21
Extranuclear functions of ER impact invasive migration and metastasis by breast cancer cells. Cancer Res (2010) 1.20
Requirement of histone methyltransferase SMYD3 for estrogen receptor-mediated transcription. J Biol Chem (2009) 1.17
Histone deacetylase 7 and FoxA1 in estrogen-mediated repression of RPRM. Mol Cell Biol (2009) 1.15
Inhibition of SIRT1 deacetylase suppresses estrogen receptor signaling. Carcinogenesis (2009) 1.11
ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor. J Cancer Res Clin Oncol (2008) 1.11
Significance of ER-Src axis in hormonal therapy resistance. Breast Cancer Res Treat (2010) 1.10
Functional connection between deimination and deacetylation of histones. Mol Cell Biol (2009) 1.10
Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole. Cancer Res (2011) 1.09
Minireview: role of kinases and chromatin remodeling in progesterone signaling to chromatin. Mol Endocrinol (2010) 1.09
Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells. Breast Cancer Res Treat (2009) 1.08
Histone deacetylase inhibitor induced modulation of anti-estrogen therapy. Cancer Lett (2009) 1.04
Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. Cancer Res (2002) 1.04
Histone deacetylase inhibition and estrogen signalling in human breast cancer cells. Biochem Pharmacol (2004) 1.03
Epigenetic regulation in estrogen receptor positive breast cancer--role in treatment response. J Mammary Gland Biol Neoplasia (2010) 1.02
Histone deacetylase inhibitor SAHA induces ERalpha degradation in breast cancer MCF-7 cells by CHIP-mediated ubiquitin pathway and inhibits survival signaling. Biochem Pharmacol (2007) 1.00
Function of histone deacetylase 6 as a cofactor of nuclear receptor coregulator LCoR. J Biol Chem (2009) 0.99
Chromatin modification of the trefoil factor 1 gene in human breast cancer cells by the Ras/mitogen-activated protein kinase pathway. Cancer Res (2006) 0.99
The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression. Proc Natl Acad Sci U S A (2010) 0.99
Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer. Breast Cancer Res Treat (2010) 0.98
Association of steroid receptor coactivator AIB1 with estrogen receptor-alpha in breast cancer cells. Breast Cancer Res Treat (2001) 0.97
Mixed lineage leukemia histone methylases play critical roles in estrogen-mediated regulation of HOXC13. FEBS J (2009) 0.96
Novel estrogen receptor coregulators and signaling molecules in human diseases. Cell Mol Life Sci (2004) 0.95
Endocrine-resistant breast cancer: underlying mechanisms and strategies for overcoming resistance. Breast Cancer (2003) 0.93
The clinical relevance of steroid hormone receptor corepressors. Clin Cancer Res (2005) 0.93
Protein arginine methylation in estrogen signaling and estrogen-related cancers. Trends Endocrinol Metab (2009) 0.90
EZH2 regulates the transcription of estrogen-responsive genes through association with REA, an estrogen receptor corepressor. Breast Cancer Res Treat (2007) 0.89
Pak1 phosphorylation of snail, a master regulator of epithelial-to-mesenchyme transition, modulates snail's subcellular localization and functions. Cancer Res (2005) 2.09
A naturally occurring MTA1 variant sequesters oestrogen receptor-alpha in the cytoplasm. Nature (2002) 1.89
P21-activated kinase-1 phosphorylates and transactivates estrogen receptor-alpha and promotes hyperplasia in mammary epithelium. EMBO J (2002) 1.75
p21-activated kinase-1 signaling mediates cyclin D1 expression in mammary epithelial and cancer cells. J Biol Chem (2003) 1.70
Coregulation of estrogen receptor by ERBB4/HER4 establishes a growth-promoting autocrine signal in breast tumor cells. Cancer Res (2006) 1.67
Retracted Metastasis-associated protein 1 deregulation causes inappropriate mammary gland development and tumorigenesis. Development (2004) 1.67
Potential role of a novel transcriptional coactivator PELP1 in histone H1 displacement in cancer cells. Cancer Res (2004) 1.59
Estrogen attenuates ischemic oxidative damage via an estrogen receptor alpha-mediated inhibition of NADPH oxidase activation. J Neurosci (2009) 1.54
Functional inactivation of a transcriptional corepressor by a signaling kinase. Nat Struct Biol (2003) 1.50
Rapid estrogen signaling in the brain. Neurosignals (2008) 1.43
PELP1 is a reader of histone H3 methylation that facilitates oestrogen receptor-alpha target gene activation by regulating lysine demethylase 1 specificity. EMBO Rep (2010) 1.39
Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations. Clin Cancer Res (2006) 1.38
Functional interactions between the estrogen receptor coactivator PELP1/MNAR and retinoblastoma protein. J Biol Chem (2003) 1.31
Genomic loss of tumor suppressor miRNA-204 promotes cancer cell migration and invasion by activating AKT/mTOR/Rac1 signaling and actin reorganization. PLoS One (2012) 1.31
C terminus of Hsc70-interacting protein (CHIP)-mediated degradation of hippocampal estrogen receptor-alpha and the critical period hypothesis of estrogen neuroprotection. Proc Natl Acad Sci U S A (2011) 1.31
p21-activated kinase 1 interacts with and phosphorylates histone H3 in breast cancer cells. EMBO Rep (2002) 1.30
Oncogenic potential of the nuclear receptor coregulator proline-, glutamic acid-, leucine-rich protein 1/modulator of the nongenomic actions of the estrogen receptor. Cancer Res (2007) 1.28
Emerging functions of p21-activated kinases in human cancer cells. J Cell Physiol (2002) 1.25
Extranuclear functions of ER impact invasive migration and metastasis by breast cancer cells. Cancer Res (2010) 1.20
MICoA, a novel metastasis-associated protein 1 (MTA1) interacting protein coactivator, regulates estrogen receptor-alpha transactivation functions. J Biol Chem (2003) 1.15
The cell fate determination factor DACH1 is expressed in estrogen receptor-alpha-positive breast cancer and represses estrogen receptor-alpha signaling. Cancer Res (2009) 1.14
Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis. Clin Cancer Res (2011) 1.14
Proline-, glutamic acid-, and leucine-rich protein-1 is essential in growth factor regulation of signal transducers and activators of transcription 3 activation. Cancer Res (2005) 1.13
Upstream determinants of estrogen receptor-alpha regulation of metastatic tumor antigen 3 pathway. J Biol Chem (2004) 1.12
B7-H1-dependent sex-related differences in tumor immunity and immunotherapy responses. J Immunol (2010) 1.10
Significance of ER-Src axis in hormonal therapy resistance. Breast Cancer Res Treat (2010) 1.10
Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer. Breast Cancer Res (2012) 1.08
Cyclin-dependent kinase-mediated phosphorylation plays a critical role in the oncogenic functions of PELP1. Cancer Res (2010) 1.08
Therapeutic significance of estrogen receptor β agonists in gliomas. Mol Cancer Ther (2012) 1.07
Growth factor regulation of estrogen receptor coregulator PELP1 functions via Protein Kinase A pathway. Mol Cancer Res (2008) 1.07
Role of estrogen receptor signaling in breast cancer metastasis. Int J Breast Cancer (2011) 1.06
Proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor enhances androgen receptor functions through LIM-only coactivator, four-and-a-half LIM-only protein 2. Mol Endocrinol (2006) 1.06
Role of PELP1/MNAR signaling in ovarian tumorigenesis. Cancer Res (2008) 1.05
Significance of PELP1 in ER-negative breast cancer metastasis. Mol Cancer Res (2011) 1.02
Modulation of in situ estrogen synthesis by proline-, glutamic acid-, and leucine-rich protein-1: potential estrogen receptor autocrine signaling loop in breast cancer cells. Mol Endocrinol (2007) 1.01
Cloning and functional characterization of PELP1/MNAR promoter. Gene (2004) 0.99
PELP1 oncogenic functions involve CARM1 regulation. Carcinogenesis (2013) 0.99
PELP1: A novel therapeutic target for hormonal cancers. IUBMB Life (2010) 0.98
Regulation of phosphoglucomutase 1 phosphorylation and activity by a signaling kinase. Oncogene (2004) 0.98
Metastasis-associated protein 1 interacts with NRIF3, an estrogen-inducible nuclear receptor coregulator. Mol Cell Biol (2004) 0.98
Essential functions of p21-activated kinase 1 in morphogenesis and differentiation of mammary glands. J Cell Biol (2003) 0.97
Five friends of methylated chromatin target of protein-arginine-methyltransferase[prmt]-1 (chtop), a complex linking arginine methylation to desumoylation. Mol Cell Proteomics (2012) 0.97
Extranuclear coactivator signaling confers insensitivity to tamoxifen. Clin Cancer Res (2009) 0.97
Identifying the estrogen receptor coactivator PELP1 in autophagosomes. Cancer Res (2007) 0.95
PELP1--a novel estrogen receptor-interacting protein. Mol Cell Endocrinol (2008) 0.95
Hepatocyte growth factor-regulated tyrosine kinase substrate (HRS) interacts with PELP1 and activates MAPK. J Biol Chem (2005) 0.94
Cloning, expression, and localization of MNAR/PELP1 in rodent brain: colocalization in estrogen receptor-alpha- but not in gonadotropin-releasing hormone-positive neurons. Endocrinology (2005) 0.93
The clinical relevance of steroid hormone receptor corepressors. Clin Cancer Res (2005) 0.93
Role of central beta-adrenergic receptors in regulating proinflammatory cytokine responses to a peripheral bacterial challenge. Brain Behav Immun (2008) 0.92
Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells. Breast Cancer Res (2011) 0.89
9-cis-retinoic acid up-regulates expression of transcriptional coregulator PELP1, a novel coactivator of the retinoid X receptor alpha pathway. J Biol Chem (2006) 0.88
HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humans. EBioMedicine (2015) 0.88
Regulation of rDNA transcription by proto-oncogene PELP1. PLoS One (2011) 0.88
Altered localization of a coactivator sensitizes breast cancer cells to tumor necrosis factor-induced apoptosis. Mol Cancer Ther (2006) 0.87
Comprehensive analysis of recent biochemical and biologic findings regarding a newly discovered protein-PELP1/MNAR. Clin Exp Metastasis (2006) 0.87
Activating transcription factor 4 overexpression inhibits proliferation and differentiation of mammary epithelium resulting in impaired lactation and accelerated involution. J Biol Chem (2003) 0.86
Dynein light chain 1 phosphorylation controls macropinocytosis. J Biol Chem (2004) 0.85
KDM1 is a novel therapeutic target for the treatment of gliomas. Oncotarget (2013) 0.84
Hypersensitivity of the hippocampal CA3 region to stress-induced neurodegeneration and amyloidogenesis in a rat model of surgical menopause. Brain (2013) 0.83
Estrogen induces expression of BCAS3, a novel estrogen receptor-alpha coactivator, through proline-, glutamic acid-, and leucine-rich protein-1 (PELP1). Mol Endocrinol (2007) 0.83
Estrogen receptor-β activation in combination with letrozole blocks the growth of breast cancer tumors resistant to letrozole therapy. Steroids (2011) 0.82
Estrogen receptor-beta mediates the protective effects of aromatase induction in the MMTV-Her-2/neu x aromatase double transgenic mice. Horm Cancer (2012) 0.82
Novel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cells. Breast Cancer Res Treat (2015) 0.80
Design of a paclitaxel prodrug conjugate for active targeting of an enzyme upregulated in breast cancer cells. Mol Pharm (2014) 0.80
Regulation of hormonal therapy resistance by cell cycle machinery. Gene Ther Mol Biol (2008) 0.79
Integrin-linked kinase 1: role in hormonal cancer progression. Front Biosci (Schol Ed) (2011) 0.78
Persistent Infections with Diverse Co-Circulating Astroviruses in Pediatric Oncology Patients, Memphis, Tennessee, USA. Emerg Infect Dis (2017) 0.75
Swine Influenza Virus (H1N2) Characterization and Transmission in Ferrets, Chile. Emerg Infect Dis (2017) 0.75
ZD6474 coerces breast cancer for an apoptotic journey. Cancer Biol Ther (2010) 0.75